Abstract
In a previously performed small-scale clinical study, healthy volunteers were asked to ingest an oral solution of itraconazole (Sporanox®) containing 40% 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) (i) with or (ii) without a standardized volume of water (240 mL) after which gastrointestinal and blood samples were collected. Although omitting water during the administration of Sporanox® resulted in noticeably higher duodenal concentrations of itraconazole, systemic exposure was almost unaffected. It is assumed that this discrepancy can be explained by differences in the extent of entrapment of itraconazole in the duodenum caused by differential complexation depending on the concentration of cyclodextrins. To further substantiate this hypothesis, the quantification of HP-β-CD concentrations in the aspirated intestinal fluids was performed by LC-MS/MS. When comparing the intestinal concentrations of itraconazole and HP-β-CD for one single healthy volunteer (HV02) in both test conditions, an excellent correlation was observed (Spearman's rank coefficient of 0.96). Moreover, the data suggest that, similar to aqueous buffer media, also in human intestinal fluids a non-linear relationship exists between itraconazole solubility and HP-β-CD concentration (Ap-type profile; Spearman's rank coefficient of 0.78), indicating that higher order complexes are formed at higher concentrations of HP-β-CD. This difference in extent of entrapment in the inclusion complexes helps to understand the observed impact of water intake on precipitation and permeation behavior of itraconazole in man. Without water intake, higher HP-β-CD concentrations resulted in less precipitation and increased duodenal concentrations of itraconazole. On the other hand, the stronger interaction at higher HP-β-CD concentrations reduced the free fraction of the drug explaining that increased intraluminal concentrations of itraconazole were not translated into an enhanced uptake. In conclusion, quantifying the concentrations of the solubilizing agent HP-β-CD in human intestinal fluids appeared to be of crucial importance to interpret the intraluminal behavior of an orally administered cyclodextrin-based solution.
Original language | English |
---|---|
Pages (from-to) | 231-236 |
Number of pages | 6 |
Journal | European Journal of Pharmaceutics and Biopharmaceutics |
Volume | 132 |
Early online date | 27 Jun 2018 |
DOIs | |
Publication status | Published - Nov 2018 |
Funding
This work has received support from (1) the Innovative Medicines Initiative Joint Undertaking ( http://www.imi.europe.eu ) under Grant Agreement No. 115369 , resources of which are composed of financial contribution from the European Union’s Seventh Framework Program and EFPIA companies’ in kind contribution and from (2) the Institute for the Promotion of Innovation though Science and Technology in Flanders (IWT) (Grant No. 135040 ).
Funders | Funder number |
---|---|
Institute for the Promotion of Innovation though Science and Technology in Flanders | |
Seventh Framework Programme | |
European Federation of Pharmaceutical Industries and Associations | |
Agentschap voor Innovatie door Wetenschap en Technologie | 135040 |
Seventh Framework Programme | |
Innovative Medicines Initiative | 115369 |
Keywords
- Clinical trial
- Human intestinal fluids (HIF)
- Hydroxypropyl-β-cyclodextrin (HP-β-CD)
- Itraconazole
- LC-MS/MS